What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
His primary scientific interests are in Chemotherapy, Surgery, Internal medicine, Oncology and Cancer.
As part of his studies on Chemotherapy, he often connects relevant subjects like Toxicity.
His studies deal with areas such as Carcinoma and Urology as well as Surgery.
His study in Gastroenterology extends to Internal medicine with its themes.
His study on Overall survival is often connected to Ethical concerns as part of broader study in Oncology.
Maurie Markman has included themes like MEDLINE, Family medicine, Laparotomy, Disease and Radiation therapy in his Cancer study.
His most cited work include:
- Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group (869 citations)
- Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. (667 citations)
- Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study (620 citations)
What are the main themes of his work throughout his whole career to date?
Maurie Markman mainly focuses on Internal medicine, Oncology, Chemotherapy, Ovarian cancer and Surgery.
Many of his studies on Internal medicine apply to Gastroenterology as well.
The various areas that Maurie Markman examines in his Oncology study include Malignancy, Hematology, Clinical trial and Drug.
As part of the same scientific family, Maurie Markman usually focuses on Chemotherapy, concentrating on Toxicity and intersecting with Pharmacology.
Within one scientific family, he focuses on topics pertaining to Peritoneal cavity under Ovarian cancer, and may sometimes address concerns connected to Pharmacokinetics.
Surgery is often connected to Urology in his work.
He most often published in these fields:
- Internal medicine (55.75%)
- Oncology (41.07%)
- Chemotherapy (37.10%)
What were the highlights of his more recent work (between 2006-2020)?
- Internal medicine (55.75%)
- Oncology (41.07%)
- Cancer (24.60%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Oncology, Cancer, Intensive care medicine and Ovarian cancer.
His Internal medicine study frequently draws connections between adjacent fields such as Gynecology.
Maurie Markman combines subjects such as Carboplatin, Paclitaxel, MEDLINE and Stage with his study of Oncology.
His studies deal with areas such as Clinical research, Physical therapy and Family medicine as well as Cancer.
In his study, Randomized controlled trial is strongly linked to Clinical trial, which falls under the umbrella field of Ovarian cancer.
His Chemotherapy study contributes to a more complete understanding of Surgery.
Between 2006 and 2020, his most popular works were:
- Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study (620 citations)
- Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer (276 citations)
- Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology (269 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
